Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 14

Results For "MOMENTUM"

229 News Found

Economic Survey 2022-23: Industry sector witness growth of 4.1%
Policy | February 01, 2023

Economic Survey 2022-23: Industry sector witness growth of 4.1%

The Survey highlighted that Indian pharmaceutical exports achieved a healthy growth of 24 per cent in FY21 and expressed hope that India’s domestic pharmaceutical market is estimated to grow to US $65 billion by 2024 from estimated US $41 billion in 2021


G20: Medical Value Travel is an essential component for idealistic healthcare to address disparities of healthcare systems: Kotecha
Policy | January 21, 2023

G20: Medical Value Travel is an essential component for idealistic healthcare to address disparities of healthcare systems: Kotecha

Multilateral collaborations will serve to strengthen knowledge sharing to formulate framework for accessible, affordable, and quality healthcare


USFDA inspections gather pace; Indian pharma companies equipped to handle disruptions
Drug Approval | January 17, 2023

USFDA inspections gather pace; Indian pharma companies equipped to handle disruptions

The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22


Moderna announces advances across mRNA pipeline
News | January 10, 2023

Moderna announces advances across mRNA pipeline

Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients


Mandaviya asserts govt's commitment towards improving access to quality medical education
Policy | December 16, 2022

Mandaviya asserts govt's commitment towards improving access to quality medical education

India now has 648 medical colleges in 2022 with a whopping 96% increase in the number of Government Medical Colleges (GMC) alone and a 42% increase in the private sector, since 2014


GSK’s new data underscore important responses with momelotinib for myelofibrosis patients
Clinical Trials | December 12, 2022

GSK’s new data underscore important responses with momelotinib for myelofibrosis patients

48-week data from MOMENTUM phase III clinical trial show momelotinib maintained total symptom response


PM addresses valedictory function of 9th World Ayurveda Congress
Policy | December 12, 2022

PM addresses valedictory function of 9th World Ayurveda Congress

Expressed happiness that more than 30 countries of the world have given recognition to Ayurveda as a traditional system of medicine


EMA accepts marketing authorisation application for momelotinib for the treatment of myelofibrosis
News | December 05, 2022

EMA accepts marketing authorisation application for momelotinib for the treatment of myelofibrosis

Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints


Strong order book in CMO segments for J.B. Chemicals & Pharmaceuticals, says Prabhudas Lilladher
News | November 15, 2022

Strong order book in CMO segments for J.B. Chemicals & Pharmaceuticals, says Prabhudas Lilladher

The company sees the business reaching $100mn